Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer
1. Ribociclib plus letrozole provides significant overall survival benefit as compared to letrozole alone in patients with advanced breast cancer. ...
Tag: advanced breast cancer
#VisualAbstract: Fulvestrant plus cyclin-dependent kinase 4/6 inhibitors improves survival in HR⁺, HER2- metastatic breast cancer
Click to read this study in Lancet Oncology.
#VisualAbstract: Internal mammary node irradiation improves survival for patients with centromedially located node-positive breast cancer
Click to read this study in JAMA Oncology.
#VisualAbstract: Exemestane plus etinostat does not improve survival compared to exemestane alone for HR⁺ advanced breast cancer
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Fulvestrant-palbociclib and letrozole-palbociclib are equally effective for HR⁺ advanced breast cancer
Click here to read this study in JAMA Oncology.
#VisualAbstract: Addition of everolimus to letrozole improves survival in patients with HR⁺ breast cancer and disease progression on tamoxifen
Click to read this study in JAMA Oncology.
#VisualAbstract: Trastuzumab emtansine monotherapy is noninferior to standard neoadjuvant therapy for ERBB2+ breast cancer
Click to read the study in JAMA Oncology.
Tamoxifen decreases recurrence rates at 25 years in lymph node-negative estrogen-receptor-positive and Erb-B2 Receptor Tyrosine Kinase 2-negative breast cancer
1. Tamoxifen reduced the long-term risk of breast cancer metastasis or recurrence and improved survival, especially in large, low-grade progesterone ...
#VisualAbstract: Pyrotinib plus capecitabine improves progression-free survival in HER2⁺ metastatic breast cancer
Click to read the study in The Lancet Oncology.
#VisualAbstract: Aromatase inhibitors superior to tamoxifen for progression-free survival in HR⁺ advanced breast cancer
Click to read the study in the European Journal of Cancer.